Palbociclib Tablet Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 75 mg, 100mg, 125 mg
Reference Brands: Ibrance® (US & EU)
Category: Oncology Cancer Care
Palbociclib Tablet is available in Oral Tablets and strengths such as 75 mg, 100mg, 125 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Palbociclib Tablet is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Palbociclib Tablet can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Palbociclib Tablets are a CDK 4/6 inhibitor used for the treatment of hormone receptor-positive (HR+), HER2-negative breast cancer. It works by blocking the proteins responsible for cancer cell division, halting cell cycle progression. Marketed under the brand name Ibrance®, Palbociclib is typically used in combination with letrozole or fulvestrant for the treatment of advanced or metastatic breast cancer. Available in 125 mg, 100 mg, and 75 mg tablet strengths, Palbociclib is manufactured in GMP-compliant facilities, making it a reliable and effective solution for oncology treatment in both US and EU markets.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers